Acne, a scourge of adolescence, may be about to meet its ultra high-tech match. By using a combination of ultrasound, gold-covered particles and lasers, researchers from UC Santa Barbara and the private medical device company Sebacia have developed a targeted therapy that could potentially lessen the frequency and intensity of breakouts, relieving acne sufferers the discomfort and stress of dealing with severe and recurring pimples.
A new technique to create tissue-engineered bladders has been shown to decrease scarring and significantly increase tissue growth. The bladders are produced using scaffolds coated with anti-inflammatory peptides.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia.
LamdaGen Corporation, a nano-technology platform company that provides LSPR based plasmonic sensors and systems for In Vitro Diagnostics (IVD), announced the opening of a wholly-owned subsidiary, LamdaGen Nanotechnology Taiwan Co., LTD. (LamdaGen Taiwan).
According to a new market research report "Nanotechnology in Medical Devices Market by Product (Biochip, Implant Materials, Medical Textiles, Wound Dressing, Cardiac Rhythm Management Devices, Hearing Aid), Application (Therapeutic, Diagnostic, Research) - Global Forecast to 2019", published by MarketsandMarkets, the Nanotechnology in Medical Devices Market is was valued at around $5 Billion in 2014 and expected to reach around $8.5 Billion by 2019 with a CAGR of around 11-12% during the forecast period 2014 - 2019.
David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor.
Nanotherapeutics, Inc., an integrated biopharmaceutical company with a focus on advanced development and manufacturing, announced today that it has secured a $28.5 million debt financing from White Oak Global Advisors, LLC. The funds will support the completion of the Company’s 180,000 sq. ft. flexible biologics manufacturing facility located in Alachua.
Diagnosis and Drug Delivery for diseases like cancer, cardiovascular and genetic ailments have always been a concern. In recent years, however, new strides and developments in the Nano-Medicine Market have facilitated more effective diagnosis and drug delivery for diseases.
Immune Pharmaceuticals Inc. ("Immune", the "Company") announced today that it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents in order to facilitate the development of a topical nanoparticle formulation of Immune's neuropathic pain drug, AmiKet™.
The directors and management of N1 Technologies Inc. have just filed a Patent for a revolutionary nano engineered super glass called "TungstenGlass." The company has developed a next generation nano based glass that features high impact and torsion resistance along with enhanced electrical properties.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.